Editorial
A richer understanding of intratumoral heterogeneity: single-cell genomics put it within reach
Abstract
The advent of targeted therapeutics has brought unprecedented benefit to selected patients and pushed anticancer treatment shifting towards personalized and precise approaches (1). At the same time, their inherited limitations, mainly referring to acquired resistance, have largely increased our appreciation of intratumoral heterogeneity.
